Histotripsy is a non-invasive cancer treatment that uses ultrasound to break up tumors in the body. It uses controlled sound waves to create micro-bubbles to destroy the targeted diseased tissue, eliminating the use of radiation, chemotherapy and surgical incisions. It was developed over 20 years ago by Michigan Engineering researchers in collaboration with clinicians @MichiganMedicine and the U-M Rogel Cancer Center, and later brought to clinical use by Minneapolis based company HistoSonics. [ Ссылка ]

After successful clinical trials in Europe and the United States, where HistoSonics Edison Platform was used to treat patients with metastatic liver tumors, the Food and Drug Administration has approved the use of histotripsy in hospitals worldwide. With the FDA approval, Histosonics can now sell the Edison Platform to hospitals, giving liver cancer patients a non-invasive treatment option.

This research was led by:
Zhen Xu, professor of biomedical engineering
[ Ссылка ]

Mishal Mendiratta-Lala, MD, Clinical Associate Professor, Radiology, Michigan Medicine
Director, Abdominal Magnetic Resonance Imaging
Division of Abdominal Radiology
[ Ссылка ]

Learn more:
[ Ссылка ]
HistoSonics: [ Ссылка ]
Zhen Xu’s Lab: [ Ссылка ]

Questions about receiving histotripsy treatment?
The Rogel Cancer Center @MichiganMedicine has put together this FAQ for questions about histotripsy liver cancer treatment at the University of Michigan. [ Ссылка ]

HistoSonics, the company that developed the Edison platform, has this page to locate Edison system histotripsy providers: [ Ссылка ]

------
Watch more videos from Michigan Engineering and subscribe: @MichiganEngineering

The University of Michigan College of Engineering is one of the world’s top engineering schools. Michigan Engineering is home to 14 highly-ranked departments, and its research budget is among the largest of any public university.
[ Ссылка ]

Follow Michigan Engineering:
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]

свернуть